喀什割包茎需花多少钱喀什男科去哪家治,喀什手术做包茎过长,喀什包皮手术手术多钱,喀什哪个医院看男科好些,喀什怀孕试纸两条杠,喀什咨询男科病,喀什验孕纸红线一深一浅

SYDNEY, Aug. 5 (Xinhua) -- The Western Australian Government announced on Friday that 14 new substances linked to the manufacture of the synthetic drug Kronic would be banned from Friday midnight.The State Mental Health Minister Helen Morton told the Australian Broadcasting Corporation (ABC) Radio on Friday morning that two substances found in Kronic Black would be banned from midnight tonight (Friday night), as well as another 12 others found in synthetic cannabis products.People caught in possession of banned synthetic cannabis face hefty fines or possible jail sentences.The government of Western Australia (WA) in June listed a number of synthetic cannabis products, including Kronic, Voodoo and Mango Kush, as illegal substances.But synthetic drug makers have since released a new product, Kronic Black Label, using a different blend of chemicals they say make it still legal to sell.Police suspect the death of a 38-year-old Perth man is linked to his smoking of the synthetic cannabis product Kronic Black Label, which contains two of the 14 substances to be banned.The man, from Hillman in Perth's south, was rushed to Rockingham Hospital on Thursday night after suffering a suspected cardiac arrest, but he later died.Police now are conducting an investigation to identify the cause of the man's death.The Australian Medical Association has warned that synthetic drugs could cause severe paranoia, anxiety and panic attacks.

BEIJING, Sept. 14 (Xinhuanet) -- The U.S. Food and Drug Administration (FDA) on Monday announced a recall on a drug infusion pump of Medtronic, the Associated Press reported.The recalled drug pump was called "SynchroMed II", including models of 8637-20 and 8637-40, distributed between 2004 and July 2011.Drug infusion pump was used to deliver the drugs for patients to treat chronic pain, spasms as well as other conditions.The pumps' malfunction could put patients in the risk of either recurrent or withdrawal symptoms, which could be life-threatening, FDA warned.There were 55 reported cases and one death related to the drug withdrawal, among a total 139,653 SynchroMed II pump implants worldwide, FDA notified.The problem was due to a film within the pump's battery that could stop the therapy, FDA said.Medtronic, the U.S. medical technology company based in Minneapolis, is not recommending patients to remove the pumps, but instead, encourage patients to contact their doctor if they hear the device alarm.

CHICAGO, Aug. 25 (Xinhua) -- Gold futures on the COMEX Division of the New York Mercantile Exchange on Thursday bounced off the biggest drop since March 2008, as the weakness in stock market enhanced appeal of gold as a safe-have investment.The most active gold contract for Dec. delivery gained 5.9 U.S. dollars, or 0.3 percent, to 1,763.2 dollars per ounce. The metal suffered on Wednesday the biggest one-day drop since March 19, 2008.Market analysts said that gold extended losses in earlier trading, hit by a margin-requirement increase, but the drop in global stock market gave a push to the metal. Both Dow Jones industrial average and S&P 500 declined on Thursday after a 3-day rise as a government report showed U.S. jobless claims rose last week.Besides, market hearsay went that Germany might be next to get a sovereign-debt downgrade, adding to the positive tone on gold market. German equity market also suffered sharp drop in the day.Many market watchers remained long-term bullish attitude toward gold although they said the precious metal could correct further in the short term. A trader noted that the fundamental factors driving uncertainty and fears are all still there.Expectations are growing that the Federal Reserve Chairman Ben Bernanke would not provide any form of stimulus in a speech scheduled for Friday at a yearly gathering of central bankers in Jackson Hole.Silver for Sept. delivery also rose 1.583 dollars, or four percent, to 40.745 dollars per ounce. Platinum for Oct. delivery lost 3.9 dollars, or 0.2 percent, to 1822.4 dollars per ounce.

BERLIN, June 1 (Xinhua) -- Germany's disease control center reported on Wednesday 365 new cases of the fatal enterohemorrhagic E. coli (EHEC), which marked a sharp rise since its outbreak in the middle of May.Twenty-five percent of the new cases involved the hemolytic- uremic syndrome (HUS), a serious complication resulting from E. coli infection that affects the blood and kidneys, Germany's Robert Koch Institute said.Until now 17 people in Europe, one in Sweden, the other in Germany have been killed by the deadly disease, while the source of the infection was still not identified.According to the data of Robert Koch Institute, at present 470 patients are suffering from HUS due to the infection, raising concerns that the death toll could be even higher in the future.Germany's Agriculture and Consumer Protection Minister Ilse Aigner defended Germany's previous alert on cucumbers from Spain on Wednesday."The fatal strain of EHEC bacteria was indeed found on Spanish cucumbers. According to the European rules, a quick warning must be sent out," she told a local TV station.Laboratory tests in Hamburg on Tuesday overthrew the previous finding that Spanish cucumbers were the sources of the outbreak.As a result of the alert, Europe and Russia imposed bans on Spanish vegetables, leaving Spanish farmers a loss of 200 million euros (287.5 million U.S. dollars) a week.Spain has expressed its intention to take possible legal actions against authorities in Hamburg and ask for compensations from Germany and the European Union.

LOS ANGELES, July 18 (Xinhua) -- U.S. scientists have proven that oncogenes can change normal cells into stem-like cells, paving the way to a safer and more practical approach to treating diseases like multiple sclerosis and cancer with stem cell therapy.In a collaborative study, researchers from the Keck School of Medicine of the University of Southern California (USC), and the Children's Hospital of Orange County (CHOC) in California and Good Samaritan Hospital Medical Center in New York have successfully converted human skin cells into brain cells by suppressing the expression of p53, a protein encoded by a widely studied oncogene. This suggests that p53 mutation helps determine cell fate -- good or bad -- rather than only the outcome of cancer.Oncogenes are generally thought to be genes that, when mutated, change healthy cells into cancerous tumor cells.Study findings were appearing Monday on the website of the American Association for the Advancement of Science (AAAS)."The reality may be more complicated than people think," said Jiang F. Zhong, Ph.D., assistant professor of pathology at the Keck School. "What is a stem cell gene? What is a cancer gene? It may be the same thing.""When you turn off p53, people think the cell becomes cancerous because we tend to focus on the bad thing," Zhong said. "Actually, the cell becomes more plastic and could do good things, too. Let's say the cell is like a person who loses his job (the restriction of p53). He could become a criminal or he could find another job and have a positive effect on society. What pushes him one way or the other, we don't know because the environment is very complicated."Stem cells can divide and differentiate into different types of cells in the body. In humans, embryonic stem cells differentiate into three families, or germ layers, of cells. The reasons why and how certain stem cells differentiate into particular layers are not clearly understood. However, from those layers, tissues and organs develop. The endoderm, for example, leads to formation of the stomach, colon and lungs, while the mesoderm forms blood, bone and heart tissue. In its study, Zhong's team examined human skin cells, which are related to brain and neural cells from the ectoderm.When p53 was suppressed, the skin cells developed into cells that looked exactly like human embryonic stem cells. But, unlike other man-made stem cells that are "pluripotent" and can become any other cells in the body, these cells differentiated only into cells from the same germ layer, ectoderm."IPSCs (induced pluripotent stem cells) can turn into anything, so they are hard to control," Zhong said. "Our cells are staying within the ectoderm lineage."Zhong said he expects that suppressing other oncogenes in other families of cells would have the same effect, which could have critical significance for stem cell therapy. Future research should focus on determining which genes to manipulate, Zhong said.The study is slated to appear in the Proceedings of the National Academy of Sciences later this month, according to AAAS.